Arcus Biosciences (RCUS) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Arcus Biosciences (RCUS) Net Income towards Common Stockholders Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 92.37% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 151.28% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -99.90% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -12.04% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 327.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 95.87% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.29% |
| Dec 31, 2025 | -12.77% |
| Sep 30, 2025 | -46.74% |
| Mar 31, 2025 | -2,700.00% |
| Dec 31, 2024 | -16.05% |
| Sep 30, 2024 | -29.58% |
| Jun 30, 2024 | -24.00% |
| Mar 31, 2024 | 95.00% |
| Dec 31, 2023 | -20.90% |
| Sep 30, 2023 | -9.23% |
| Jun 30, 2023 | -11.94% |
| Mar 31, 2023 | -17.65% |
| Dec 31, 2022 | -123.97% |
| Sep 30, 2022 | 16.64% |
| Jun 30, 2022 | 11.81% |
| Mar 31, 2022 | 6.33% |
| Dec 31, 2021 | 617.12% |
| Sep 30, 2021 | -4,379.64% |
| Jun 30, 2021 | -68.55% |
| Mar 31, 2021 | -161.57% |